Commentary on "Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma".
作者信息
Peña-Cardelles Juan Francisco, Moro-Rodríguez José Ernesto, Cebrián-Carretero José Luís, Pozo-Kreilinger José Juan
机构信息
Oral surgery and Implantology Department, Universidad Rey Juan Carlos, Faculty of Health Sciences, University Clinic, Av. de Atenas, S/N, 28922 Alcorcón, Madrid, Spain.
Oral and Maxillofacial Surgery Division and Prosthodontics Division, School of Dental Medicine, University of Connecticut, Connecticut, United States.
出版信息
Open Med (Wars). 2022 Feb 1;17(1):227-228. doi: 10.1515/med-2022-0431. eCollection 2022.
Abstract
摘要
相似文献
1
Commentary on "Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma".关于“口腔鳞状细胞癌患者程序性细胞死亡配体1表达的临床病理特征”的评论
Open Med (Wars). 2022 Feb 1;17(1):227-228. doi: 10.1515/med-2022-0431. eCollection 2022.
2
Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717).对《程序性死亡配体-1表达与口腔鳞状细胞癌患者临床病理特征及预后的关系：一项荟萃分析》（何等人，（2020年）《口腔生物学档案》，第114卷，第104717页）的评论
Arch Oral Biol. 2021 Dec;132:105274. doi: 10.1016/j.archoralbio.2021.105274. Epub 2021 Oct 8.
3
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.程序性死亡配体-1 表达与口腔鳞状细胞癌患者临床病理特征及预后的关系：荟萃分析。
Arch Oral Biol. 2020 Jun;114:104717. doi: 10.1016/j.archoralbio.2020.104717. Epub 2020 Apr 11.
4
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.程序性死亡受体-1 及其配体程序性死亡配体-1 在有和无口腔黏膜下纤维性变的口腔鳞状细胞癌中的差异表达。
Arch Oral Biol. 2020 Nov;119:104916. doi: 10.1016/j.archoralbio.2020.104916. Epub 2020 Sep 17.
5
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.程序性细胞死亡配体 1 在口腔鳞状细胞癌和口腔白斑病中的表达与疾病进展和 CD8+肿瘤浸润淋巴细胞有关。
Pathol Res Pract. 2019 Jun;215(6):152418. doi: 10.1016/j.prp.2019.04.010. Epub 2019 Apr 18.
6
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.程序性细胞死亡配体1（PD-L1）表达在食管鳞状细胞癌患者中的临床病理及预后意义：一项荟萃分析
J Thorac Dis. 2016 Nov;8(11):3197-3204. doi: 10.21037/jtd.2016.11.01.
7
[Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma].[口腔鳞状细胞癌中程序性死亡受体-1及其配体的研究进展]
Hua Xi Kou Qiang Yi Xue Za Zhi. 2020 Aug 1;38(4):449-453. doi: 10.7518/hxkq.2020.04.017.
8
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.程序性死亡蛋白-1和程序性死亡配体-1表达在食管鳞状细胞癌患者中的预后意义
Oncotarget. 2016 May 24;7(21):30772-80. doi: 10.18632/oncotarget.8956.
9
Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.顺铂诱导的程序性死亡配体 2 表达与口腔鳞状细胞癌的转移能力有关。
Cancer Sci. 2020 Apr;111(4):1113-1123. doi: 10.1111/cas.14336. Epub 2020 Feb 29.
本文引用的文献
1
Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717).对《程序性死亡配体-1表达与口腔鳞状细胞癌患者临床病理特征及预后的关系：一项荟萃分析》（何等人，（2020年）《口腔生物学档案》，第114卷，第104717页）的评论
Arch Oral Biol. 2021 Dec;132:105274. doi: 10.1016/j.archoralbio.2021.105274. Epub 2021 Oct 8.
2
Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.口腔鳞状细胞癌患者程序性细胞死亡配体1表达的临床病理特征
Open Med (Wars). 2020 Apr 17;15:292-301. doi: 10.1515/med-2020-0041. eCollection 2020.
3
Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.p16 和 PD-L1 表达对接受确定性治疗的口咽鳞状细胞癌患者的预后影响。
J Clin Pathol. 2019 Aug;72(8):542-549. doi: 10.1136/jclinpath-2019-205818. Epub 2019 May 21.
4
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.PD-L1 表达与人类乳头状瘤病毒阳性的显著相关性及其在口咽癌中的预后影响。
Oral Oncol. 2019 May;92:33-39. doi: 10.1016/j.oraloncology.2019.03.012. Epub 2019 Mar 18.
5
Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years.是时候改变对口咽癌中人乳头瘤病毒（HPV）的看法了。对过去三年每个口咽亚部位的HPV患病率进行的系统评价。
Papillomavirus Res. 2017 Dec;4:1-11. doi: 10.1016/j.pvr.2017.05.002. Epub 2017 May 19.
6
Tumor PD-L1 status and CD8 tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer.肿瘤程序性死亡受体配体1（PD-L1）状态与CD8肿瘤浸润性T细胞：口咽癌预后改善的标志物
Oncotarget. 2017 Jul 6;8(46):80443-80452. doi: 10.18632/oncotarget.19045. eCollection 2017 Oct 6.
7
Prevalence of human papillomavirus16 DNA and p16 protein in oral squamous cell carcinoma: A systematic review and meta-analysis.人乳头瘤病毒16型DNA和p16蛋白在口腔鳞状细胞癌中的患病率：一项系统评价和荟萃分析。
J Oral Maxillofac Pathol. 2017 Jan-Apr;21(1):76-81. doi: 10.4103/jomfp.JOMFP_248_16.
8
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.第八版 AJCC 癌症分期手册：继续从基于人群的方法向更“个体化”的癌症分期方法构建桥梁。
CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17.
9
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.扁桃体癌中程序性死亡受体配体1（PD-L1）的表达与人乳头瘤病毒阳性及生存改善相关：对抗程序性死亡蛋白1（PD-1）临床试验的意义
Oncotarget. 2016 Nov 22;7(47):77010-77020. doi: 10.18632/oncotarget.12776.
10
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.程序性死亡受体配体1（PD-L1）的表达与头颈部鳞状细胞癌的上皮-间质转化相关。
Oncotarget. 2016 Mar 29;7(13):15901-14. doi: 10.18632/oncotarget.7431.
Zotero 插件